key: cord-0267307-1l8oc8p9
authors: Le Bert, Nina; Tan, Anthony; Kunasegaran, Kamini; Chia, Adeline; Tan, Nicole; Chen, Qi; Hang, Shou Kit; Qui, Martin DC; Chan, Bianca SW; Low, Jenny GH; Young, Barnaby; Ng, Kee Chong; Chan, Derrick Wei Shih; Lye, David Chien; Bertoletti, Antonio
title: Mutations of SARS-CoV-2 variants of concern escaping Spike-specific T cells
date: 2022-01-25
journal: bioRxiv
DOI: 10.1101/2022.01.20.477163
sha: e6de9dc45e2884e4b5a500837b8e83985560b45a
doc_id: 267307
cord_uid: 1l8oc8p9

The amino acid (AA) mutations that characterise the different variants of concern (VOCs), which replaced the ancestral SARS-CoV-2 Wuhan-Hu-1 isolate worldwide, provide biological advantages such as increased infectivity and partial escape from humoral immunity. Here we analysed the impact of these mutations on vaccination- and infection-induced Spike-specific T cells. We confirmed that, in the majority of infected or vaccinated individuals, different mutations present in a single VOC (Delta) or a combined mosaic of more than 30 AA substitutions and deletions found in Alpha, Beta, Gamma, Delta and Omicron VOCs cause modest alteration in the global Spike-specific T cell response. However, distinct numerically dominant Spike-specific CD4 and CD8 T cells preferentially targeted regions affected by AA mutations and do not recognise the mutated peptides. Importantly, some of these mutations, such as N501Y (present in Alpha, Beta, Gamma, and Omicron) and L452R (present in Delta), known to provide biological advantage to SARS-CoV-2 in terms of infectivity also abolished CD8 T cell recognition. Taken together, our data show that while global mRNA vaccine- and infection-induced Spike-specific T cells largely tolerate the diverse mutations present in VOCs, single Spike-specific T cells might contribute to the natural selection of SARS-CoV-2 variants.

Living organisms, including viruses, constantly evolve to adapt to their environment.

They acquire random mutations during replication and deleterious or neutral mutations are purged. Mutations that aid to their spread and persistence 1 and provide a selective advantage become dominant 2,3 .

The current SARS-CoV-2 pandemic illustrates this phenomenon: after an initial year of relative evolutionary stasis, variants have emerged to replace the initial SARS-CoV-2 Wuhan-Hu-1 strain 2,3 . In July 2021 SARS-CoV-2 variants of concern (VOCs) The selection of these variants likely occurs due to the combined effect of immunological pressure and acquisition of advantages in transmissibility and fitness 1, 5 .

Amino acid (AA) variations occur throughout the entire genome 2,3 , however, the moststudied mutations are in the Spike protein [6] [7] [8] [9] [10] [11] . Some mutations increase binding to the ACE-2 receptor [12] [13] [14] , while others reduce antibody neutralization 6, 9, 11, 15 .

In contrast, the role of SARS-CoV-2-specific T cells in selection pressure has been largely discounted, despite scattered observations that mutations can affect T cell recognition 9, 12, 16, 17 . The main argument is that T cells recognise various epitopes in vaccinated and convalescent individuals 7, 18, 19 . As such, VOC-mutations are unlikely to alter all of them 7, 10 . This argument is supported by recent reports documenting the ability of Spike-specific T cells to tolerate the high number of mutations present in Omicron 20-26 , and likely the immunological basis of why vaccinations are still highly effective against VOCs in reducing severe COVID-19 27 .

However, the role for multi-specific antiviral immunity is not involvement in the selection process of VOCs should not be entirely discounted. Both, humoral and cellular immunity are multi-specific 28, 29 and while most VOCs fully escape recognition of monoclonal antibodies 6, 30 , their ability to escape serum neutralisation from convalescent or vaccinated individuals was less dramatic 6, 15 before the surge of Omicron. In addition, a hierarchy of antiviral efficacy exists within the polyclonal cellular immune response 29 , and thus some mutations might escape the dominant antiviral T cells, similarly to what has been observed for polyclonal antibodies 15 .

To understand whether Spike-specific T cells uniformly recognise different Spike regions 29 , we designed seven pools of 33-39 overlapping 15-mer peptides covering 180-200 AA long regions (Fig S1A, Table S1 ). Peptide-reactive cells were quantified by IFN-γ ELISpot ex vivo in 35 vaccinated and 31 convalescents individuals. The mean quantity was different (Fig. S1B, S1C) , likely reflecting the time of measurement since T cell induction (3 versus 12 months, respectively). Yet, important commonalities were detected. First, as already described 31 , we found significant heterogeneity in the quantity of Spike-specific T cells (Fig. S1B, S1C) . Second, most of the individuals exhibited T cells recognising all seven distinct peptide pools (Fig. 1A ), in line with the reported T cell multi-specificity 7, 18, 19 . However, a dominant T cell response towards a single peptide pool was frequently observed. In 8/35 vaccinated and 9/31 convalescents, with T cells specific for a single pool exceeding 40% of the total Spikespecific T cell response (Fig. 1B) . The Spike region 886-1085 was the most immunogenic in both vaccinated (65%) and convalescents (34%) (Fig. 1C ). This region is fairly conserved among different VOCs, but includes the D950N, S982A and T1027I mutations in the Delta, Alpha and Gamma VOCs, respectively, and the mutations S954H, S969K, S981F in Omicron. In 16% of vaccinated and 19% of convalescents, a dominant T cell response was observed towards the region 336-510 ( Fig. 1C) , containing several VOC mutations that affect the receptor binding affinity (N501Y 13,14 , L452R 12 ), antibody (K417 32 , T478K 15 , E484K 15 ) and T cells (L452R 12 ) recognitions.

Next, we tested the effect of the mutations on Spike-specific T cells. First, we aimed to understand in 100 individuals the impact of Delta mutations on Spike-specific T cells induced by BNT162b2 vaccine. We stimulated whole blood with three peptide pools covering the whole Spike protein (253 peptides) and the regions mutated in Delta (24 peptides) with and without the AA-substitutions/deletions (Fig 2A, Table S2 ).

We measured the magnitude of the Spike-specific T cell response, its proportion targeting peptides affected by AA changes and calculated the reduction when stimulated with peptides containing Delta-specific mutations (Fig. 2B) , which was on average 3.9% (Fig. 2C) . The Spike-specific T cell response was not affected in 46% of the vaccinated individuals; 45% showed less than 10% reduction and only in 3% did we observe more than 20% reduction in Spike-specific T cells (Fig. 2D ). Of note, we confirmed in this large population that there is vast heterogeneity of the Spikespecific T cell response in different individuals (Fig. S2) .

Second, we defined the combined impact of the mutations that are characteristic of the Alpha, Beta, Gamma and Delta VOCs on Spike-specific T cells in 33 vaccinated and 29 convalescents (Fig. 2E , Table S2 ). Note, 10 of these mutations are also characteristic of the newly emergent Omicron VOC 4 ( Table S3 ). The combined effect of 30 AA mutations was tested with IFN-γ ELISpot assays.

This combination of 30 AA mutations reduced the T cell response on average by 11.9% (vaccinated, Fig 2F) and 15.6% (convalescent, Fig 2G) , a greater reduction than that detected for the Delta mutations alone (3.9%). Spike-specific T cells were not affected in 7/33 (21%) mRNA vaccinated (Fig. 2H ) and 5/29 (17%) convalescent individuals (Fig. 2I ). Less than 10% reduction was observed in 39% of vaccinated and 24% of convalescents. Only in 1 individual of both groups did the combined VOC mutations reduce the Spike-specific T cells by 50%.

Next, we characterized epitope-specificity and CD4/CD8 phenotype of vaccine-and infection-induced T cells. We utilized an unbiased approach, based on PBMC stimulation with a single peptide pool covering whole Spike and expansion of specific T cells. The T cell lines were then used to confirm the single-peptide specificity, define the phenotype of the responsive T cell (CD4/CD8) and, in selected cases, their HLA-Class I restriction ( Fig. S3-5 ). This approach allowed us to define the dominant T cell specificities, irrespective of the HLA-Class I and Class II profile of the tested individuals.

First, we showed that the expansion procedure preserved the overall hierarchy of Spike-specific T cell recognition detected ex vivo in most of the tested individuals and it was remarkably stable across different time points (Fig. 3SB ).

Subsequently, we defined the single peptide specificity and the CD4/CD8 phenotype of T cells in nine vaccinated (Fig. S3C ) and 11 convalescents (Fig. S4 ). Eighteen distinctive Spike-specific CD4 epitopes and 17 different CD8 epitopes were characterized (Fig. S3C, S4 ; Table1). HLA-Class I restriction of 6 distinct CD8 T cell lines was identified utilizing EBV-B cell lines with shared/non-shared HLA-Class I molecules (Fig. S5) .

Surprisingly, among the defined peptides containing epitopes targeted by Spikespecific T cells, 12/18 CD4 T cells and 10/17 CD8 T cells recognized peptides that contain 30 out of the 55 distinct AA mutations characteristic of the five VOCs (Table   1, Table S2 ).

The impact of the AA mutations affecting the peptide-specific T cells was analysed both directly ex vivo (Fig. 3A ) and in T cell lines (Fig. S6) . We tested 6 CD8 and 5 CD4

T cell specificities containing AA mutations. PBMCs of the individuals in whom the T cell specificities were defined were stimulated in parallel with peptides containing either the wildtype or the mutated AA sequence.

All AA mutations affected the T cell recognition with the partial exception of mutation T1027I present in S1016-30. This mutation altered T cell recognition in one out of two individuals tested. HLA-restriction (Fig. S5 ) and visualization with HLA-pentamer on the individual who tolerated T1027I (Fig. S7) showed that the T cells were B40restricted and recognized the epitope S1016-1024, which lay outside of the mutations.

The ability of the other AA mutations to inhibit T cell recognition strongly suggest that they were located within the T cell epitopes. Mutations affected both CD4 (i.e. S76-90, S206-25, S236-50) and CD8 T cell responses (i.e. S411-25, S446-60, S491-510). Of note, peptide S26-40 stimulated a CD4 and a CD8 T cell response in two different convalescents, suggesting this peptide contains two distinct epitopes. P26S strongly inhibited both CD4 and CD8 T cells.

Of particular interest, we demonstrated that HLA-A*02:05-restricted CD8 T cells specific for the peptide 411-25 were completely inhibited by Beta and Omicron mutation K417N and by Gamma mutation K417T. Moreover, we observed that the mutations L452R and N501Y, which have negligible effect on antibody recognition 33, 34 but increase the infectivity of the Delta 12 and Beta/Gamma 13,14 VOCs respectively, clearly inhibited recognition of CD8 T cells specific for the HLA-A*24:02 epitope GNYNYLYRLF and HLA-B*15:27 epitope FQPTNGVGY.

The observation that L452R and N501Y, present in Delta (L452R), Alpha, Beta, Gamma and Omicron (N501Y), respectively, increase infectivity 12 To characterize the HLA-B*15:27 restricted CD8 T cell response to the Spike region containing the mutation N501Y, we engineered T cell receptor (TCR)-redirected T cells. The alpha and beta TCR chains of T cells activated by peptide 491-505 were sequenced and cloned into a pVAX1 vector, which allowed the expression of the introduced TCR in allogenic PBMC (Fig 3D) . The TCR-redirected T cells were used to define the short epitope (FQPTNGVGY; Fig. 3E ) and we confirmed the ability of N501Y to completely abolish CD8 T cell recognition (Fig. 3F) . Titration of the peptide concentration used for T cell activation demonstrated the high affinity of the TCR, a concentration as low as 0.1 ng/ml induced a response which plateaued at 1 µg/ml (Fig.   3G ).

We designed experiments to address two questions: whether VOCs can escape the global Spike-specific T cell response induced by infection or vaccination and whether T cells can play a role in VOCs selection.

We confirmed the marked multi-specificity of Spike-specific T cells. Although we observed a hierarchy among the T cells recognizing different Spike regions, the dominant Spike-specific T cells rarely occupied more than 40% of the repertoire. Remarkably, we observed that mutations L452R (present in Delta) and N501Y

(present in Alpha, Beta Gamma and Omicron), which have negligible effect on the neutralization ability of polyclonal sera 33, 34 , but increase the binding affinity of Spike protein to the ACE2 receptor [12] [13] [14] , abolish the recognition of CD8 T cells specific for one HLA-A*24:02 (S447-56) and one HLA-B*15:27 (S497-505)-restricted epitope.

This convergence of biological effects is reminiscent of the hypothesis of the causes of influenza hemagglutinin variant selection. In animal models of Influenza, antibodies select viruses with mutations that provide a generalized advantage by increasing receptor avidity 5 .

In general, immune escape mutations affecting T cell epitopes are selected in individuals with chronic viral infections (i.e. HIV, HBV, HCV, HDV, HCMV, EBV) 37 but are unlikely to uniformly affect the wider human population. Since the biology of T cell recognition makes the T cell repertoire largely unique for each individual 29 , it is unlikely that a virus variant with a single set of immune escape mutations will affect the whole human population identically and successfully spread globally. However, if mutations permit escape from a specific T cell specificity in parallel with increasing the receptor binding affinity of Spike, as in the case of L452R and N501Y, such advantage will no longer be solely restricted to a selected population. Interestingly, recent mathematical models of SARS-CoV-2 variant spread suggested that mutations able to concurrently increase infectivity and immune escape are likely to rapidly propagate in the population 38 .

Our data do not provide the demonstration that this chain of events took place during this pandemic. Nevertheless, they indicate an alternative possibility to the prevalent theory that postulates that VOCs emerged exclusively under the pressure of neutralizing antibodies.

We made the unexpected observation that a large number of T cells (20 out of 35) selected in vitro by PBMC stimulation with whole Spike peptide pool recognized peptides carrying the VOC mutated regions of Spike. This is at odds with ex-vivo results obtained by us and others, since T cells specific for variant regions represent a minority of the global Spike T cell repertoire in the ex vivo analysis 7,18-26 . One might speculate that the in vitro expansion mimics the immunological events occurring after SARS-CoV-2 infection and, as such, the analysis of T cells after in vitro expansion selects for the dominant effector T cell response present during the acute phase of response. These dominant T cells might thus exert higher selective pressure. Future studies will be necessary to verify the robustness of the observation and its real mechanisms. However, by determining HLA-restrictions of a number of these T cell epitopes targeting mutated regions (at least for HLA-Class I), we provide the possibility to test whether, for example, breakthrough infection might occur more frequently in individuals with such HLA-Class I profiles. Finally, the demonstration that AA mutations escaping specific CD8 T cells and concomitantly offer the virus a biological advantage in term of increased infectivity 14 , provides the theoretical possibility that T cell pressure might contribute to the selection of VOCs.

There are some limitations to this study. We tested the impact of AA substitutions on Spike-specific T cells utilizing peptide-pulsed target cells and not infected cells. This method might overestimate the quantity of T cells specific for SARS-CoV-2 because low affinity T cells might have been quantified and be more sensitive to AA mutations.

On the other hand, peptide-pulsed target cells cannot be used to evaluate the impact that AA substitutions might have on the processing of T cell epitopes 37 . AA outside the T cell epitopes can alter their generation 39 Table S1 ).

To stimulate whole blood or PBMC, the peptides were divided into 7 pools of about 40

peptides. For single peptide identification, peptides were organized in a matrix of 16 numeric and 16 alphabetic pools. Peptides with and without VOC mutations were mixed into two separate pools (Table S2) .

Cytokine release assay (CRA) from whole peripheral blood: 320 μl of whole blood drawn on the same day were mixed with 80 μl RPMI and stimulated with the indicated SARS-CoV-2 Spike peptide pools at 2 μg/ml or with DMSO as a control. After 16 hours of culture, the culture supernatant (plasma) was collected and stored at −80ºC. Delta VOC peptide pool Spike-specific T cell response % of donors tested > 500 pg/mL IFN-γ = high responder 50 -500 pg/mL IFN-γ = medium responder 50 -10 pg/mL IFN-γ = low responder < 10 pg/mL IFN-γ = non responder 

Rates of evolutionary change in viruses: patterns and determinants

SARS-CoV-2 variants, spike mutations and immune escape

COVID-19, the first pandemic in the post-genomic era

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic Drift

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Sensitivity of infectious SARS-CoV-antibodies

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Confronting Complexity: Real-World Immunodominance in Antiviral CD8+ T Cell Responses

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men: Heterogenous immunity to SARS-CoV-2

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

The impact of Spike mutations on SARS-CoV-2 neutralization

SARS-CoV-2 mutations acquired in mink reduce antibodymediated neutralization

Viral immune evasion strategies and the underlying cell biology

Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape

Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance

NNATNVVIKVCEFQF 291-305 CALDPLSETKCTLKS 456-470 FRKSNLKPFERDIST 621-635 PVAIHADQLTPTWRV 816-830 SFIEDLLFNKVTLAD 1006-1020 TYVTQQLIRAAEIRA 1196-1210 SLIDLQELGKYEQYI 126-140 VVIKVCEFQFCNDPF 296-310 LSETKCTLKSFTVEK 461-475 LKPFERDISTEIYQA

 1 1  1 2  1 3  1 4  1 5  1 6  1 7  1 8  1 9  2 0  2 1  2 2  2 3  2 4  2 5  2 6  2 7  2 8  2 9  3 0  3 1  3 2  3 3  3 4  3 5  3 6  3 7  3 8  3 )  T716I  I  D796Y  Y  N856K  K  D950N  N  Q954H  H  N969K  K  L981F  F  S982A  A  T1027I  I  D1118H  H  V1176F F